Ruxolitinib, JAK inhibitor (TBI4511)

Description

Product Details

Formal Name: βR-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile

Alternate Names: INCB 018424

Molecular Formula: C₁₇H₁₈N₆

Formula Weight: 306.37

CAS Number: 941678-49-5

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).

Storage: -20°C

Stability: ≥ 1 year.

 

Applications

JAK inhibitor

 

Functions

Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively. Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM). Inhibits the proinflammatory secretome of senescent cells. The JAK1 S646P mutant is highly sensitive to ruxolitinib. Clinically useful cancer chemotherapeutic.

 

Application Procedures

First dissolved in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.

Additional information

SIZE (mg)	25 MG, 5 MG

Datasheet:

TBI4511_Ruxolitinib

MSDS:

TBI4511_Ruxolitinib_MSDS_2024